

Wednesday May 30th 2018

Arrival and registration

From
08.00

Welcome and opening remarks

Chairs: Tore B. Stage, University of Southern Denmark and Kim Brosen, University of Southern Denmark

09.30

Plenary 1 - Novel methods for assessing drug toxicity

Chair: Tore B. Stage, University of Southern Denmark

09.45

iPSC-derived sensory neurons to assess chemotherapy-induced sensory neuropathies

Deanna L. Kroetz, UCSF

From abstract: Doxorubicin uptake in cardiomyocytes is dependent on organic cation transporter 3

Kevin Huang, Ohio State University

Novel in vitro systems for better prediction of drug metabolism and hepatotoxicity

Magnus Ingelman-Sundberg, Karolinska Institutet

Coffee

11.15

Keynote 1 - Pharmacogenetics of glucose-lowering drugs

Chair: Kim Brosen, University of Southern Denmark

11.30

Pharmacogenetics of glucose-lowering drugs

Ewan Pearson, Dundee University

Lunch

12.30

Industry sponsored talk

13.15

Sensitive and fast monitoring of treatment efficiency, resistance development and disease progression using liquid biopsies from cancer patients

Ulf B. Christensen, Pentabase

Keynote 2 - Personalized medicine in oncology – success stories from the real World	13.45
<i>Chair: Tore B. Stage, University of Southern Denmark</i>	
Phenotyping and genotyping in childhood leukemia - precision medicine in an international setting <i>Kjeld Schmiegelow, Copenhagen University Hospital</i>	
Parallel 1 - Next generation sequencing and rare variants in personalized medicine	Parallel 2 - New aspects of P450 variability
<i>Chair: Magnus Ingelman-Sundberg, Karolinska Institutet</i>	<i>Chair: Janne T. Backman, University of Helsinki</i>
Integrating rare genetic variability into preemptive pharmacogenomic advice <i>Volker Lauschke, Karolinska Institutet</i>	CYP2D6 pharmacogenetics: from a scientific cornucopia towards routine clinical practice <i>Andrea Gaedigk, Children's Mercy Kansas City</i>
From abstract: Effect of rare single-nucleotide variants on the breast cancer resistance protein <i>Heidi Kidron, University of Helsinki</i>	Cytochrome P450 phenotyping and the microdosing approach <i>Gerd Mikus, Heidelberg University Hospital</i>
Twin studies and systems pharmacology as innovative tools for clinical pharmacokinetics <i>Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart and University of Tuebingen, Germany</i>	Clinical significance of cytochrome P450 mediated drug interactions <i>Kim Brøsen, University of Southern Denmark</i>
	From abstract: The protein kinase inhibitors midostaurin and nintedanib are time-dependent inhibitors of CYP3A4 <i>Anne Filppula, University of Helsinki and Helsinki University Hospital</i>
Drinks and poster viewing (presenters at posters)	16.45
Beer tasting (additional registration required)	20.00

Thursday May 31st 2018

Plenary 3 - Pharmacoepigenetics and biomarkers

09.00

Chairs: Ingolf Cascorbi, University of Kiel and Magnus Ingelman-Sundberg, Karolinska Institutet

miRNAs as mediators of drug resistance

Ingolf Cascorbi, University of Kiel

From abstract: MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma

Hanne Due, Aalborg University Hospital

DNA Methylation of ADME Genes: Clinical implications

Pascale Fisel, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart and University of Tuebingen, Germany

Diagnostic and prognostic epigenetic biomarkers in cancer.

Carmen Jerónimo, University of Porto

Coffee

11.00

Plenary 4 - Role of the gut in ADME

11.30

Chairs: Mette Marie Hougaard Christensen, Odense University Hospital and Troels Bergmann, Odense University Hospital

State of the art PBPK modelling of the metabolism and back conversion of compounds within the gastrointestinal tract

Nikunj Kumar Patel, Certara

Gut wall metabolism

Oliver Hatley, Certara

Lunch

12.30

Plenary 5 - Personalized medicine: Cardiovascular disease

13.30

Chair: Niels Jessen, Aarhus University

Protein biomarkers for cardiovascular conditions - perspectives for personalized medicine?

Lars M. Rasmussen, Odense University Hospital

From abstract: Selecting pharmacogenetic test for clopidogrel patients

Jari Forsström, Abomic Oy

Inherited cardiac diseases and personalized medicine

Henning Bundgaard, Copenhagen University Hospital

From abstract: GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists: a direct study

Adem Yesuf Dawed, University of Dundee

Key note 3 - The role of drug transporters in chemotherapy-induced toxicity

15.00

Chair: Tore B. Stage, University of Southern Denmark

The role of drug transporters in chemotherapy-induced toxicity

Alex Sparreboom, Ohio University

Poster viewing (presenters at posters)

16.00

Conference dinner - Hotel Storebælt (additional registration required)

18.30

Friday June 1st 2018

Plenary 6 - Drug transporters

09.00

Chair: Mikko Niemi, University of Helsinki

Assessing OCT-function in vivo using 11C-labeled metformin

Niels Jessen, Aarhus University

Pharmacogenomics of transporters; OATP1B1, BCRP, rare variants

Mikko Niemi, University of Helsinki

Coffee

10.15

Parallel 3 - Using big data to develop personalized medicine

Chairs: Kim Brøsen, University of Southern Denmark and Henrik Berg Rasmussen, University of Copenhagen

Personalized Medicine and big data in Immune Deficiency

Jens Lundgren, University of Copenhagen

Analyzing drug response data from medical records

Søren Brunak, University of Copenhagen

From abstract: Clinical implementation of personalized medicine by novel approaches in therapeutic drug monitoring (TDM)

Erik Eliasson, Karolinska Institutet

Danish National Health Registries and Pharmacogenetics in Psychiatry

Christiane Gasse, Aarhus University

Parallel 4 - Pharmacogenetics and adverse drug reactions

10.30

Chair: Per Damkier, Odense University Hospital

Challenges to the clinical utility of PGx in the prevention of adverse drug reactions

Henk-Jan Guchelaar, Leiden University Medical Center

Advances in PGx of adverse drug reactions

Munir Pirmohamed, University of Liverpool

From abstract: Genome-wide association study of pandemrix-induced narcolepsy in Sweden - a possible role for glial derived neurotrophic factor (GDNF)

Mia Wadelius, Uppsala University

The genetic basis of drug-induced liver injury

Ann Daly, University of Newcastle

Closing remarks and awards

12.15

Lunch – grab and go